From May 29 to June 1, 2025, the 19th Oriental Congress of Cardiology (OCC 2025) grandly commenced at the Shanghai World Expo Center. As a pioneer in innovative structural heart disease solutions, Peijia Medical made an in-depth participation with three globally pioneering products, comprehensively showcasing China's original device innovation capabilities. 

During the congress, Professor Zhou Daxin from Zhongshan Hospital presented the design and pivotal trial results of the novel third-generation non-glutaraldehyde crosslinked dry-tissue TAVR System TaurusNXT®: The one-year all-cause mortality rate in the full analysis set was 5.3%, with only one cardiac death; the technical success rate reached 94.7%, with relevant indicators meeting internationally recognized excellence standards.